WeedLife News Network
Tilray Sees Cannabis Rescheduling as Gateway to US Medical Market
Tilray Eyes Quick Entry into US Medical Cannabis Market if Federal Reclassification Occurs. Tilray Brands believes it can get into the medical marijuana business in the U.S. pretty quickly if the Biden administration reclassifies cannabis as a Schedule 3 drug sometime this year, CEO Irwin Simon
Copyright
© 420 Intel
When you subscribe to the blog, we will send you an e-mail when there are new updates on the site so you wouldn't miss them.